JCRB1851 Akata Δ2 EBER1(+)
Cell information
Important Notice(s)JCRB1851 Akata Δ2 EBER1(+)のEBV潜伏感染について
Cell type：virus production cells (View Pricing Information)
| JCRB No. | JCRB1851 | Cell Name | Akata Δ2 EBER1(+) |
|---|---|---|---|
| Profile | EBV-encoded small RNA (EBER) knockout EBV knocked in EBER1 viruses were reinfected into Akata- cell line. | Other Name | |
| Animal | human | Strain | |
| Genus | Homo | Species | sapiens |
| Sex | F | Age | 4-year-old |
| Identity | not done | Tissue for Primary Cancer | blood |
| Case history | Burkitt’s lymphoma | Metastasis | |
| Tissue Metastasized | Genetics | ||
| Life Span | infinite | Crisis PDL | |
| Morphology | lymphocyte-like | Character | |
| Classify | transformed | Established by | Kenzo Takada |
| Registered by | Kenzo Takada | Regulation for Distribution | |
| Comment | Year | 2019 | |
| Medium | RPMI1640 with 10% FBS and G418. (Lot check of FBS is important) | Methods for Passages | dilution |
| Cell Number on Passage | Race | ||
| CO2 Conc. | 5% | Tissue Sampling | blood |
| Tissue Type |
| Detection of virus genome fragment by Real-time PCR | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Detected DNA Virus | tested | Detected RNA Virus | tested | ||||||
| CMV | - | parvoB19 | - | HCV | - | HTLV-1 | - | ||
| EBV | + | HBV | - | HIV-1 | - | HTLV-2 | - | ||
| HHV6 | - | HTLV-1 | - | HIV-2 | - | HAV | - | ||
| HHV7 | - | HTLV-2 | - |
-/negative. +/positive. nt/not tested. (positive (+) does not immediately mean the production of infectious viral particles.) |
|||||
| BKV | - | HIV-1 | - | ||||||
| JCV | - | HIV-2 | - | ||||||
| ADV | - | HPV18 | - | ||||||
| Notes | |||||||||
| Reference | |
|---|---|
| Pubmed id:17686859 | Epstein-Barr virus (EBV)-encoded RNA 2 (EBER2) but not EBER1 plays a critical role in EBV-induced B-cell growth transformation. Wu Y,Maruo S,Yajima M,Kanda T,Takada K J Virol. 2007 Oct;81(20):11236-45 |
| Images |
|---|
      |
LOT Information
| Cell No. | JCRB1851 | Cell Name | Akata Δ2 EBER1(+) |
|---|---|---|---|
| LOT No. | 03122021 | Lot Specification | distribution |
| Medium | RPMI1640 medium(GIBCO：Cat No.;11875-093) with 10% heat inactivated fetal bovine serum(SIGMA,Cat#172012-500ML,Lot#12J396) and G418 700 ug/ml | Temperature | 37 C |
| Cell Density at Seeding | 0.8-2.1x10^5 cells/ml | Methods for Passages | dilution |
| Doubling Time | NT | Cell Number in Vial (cells/1ml) | 2.3x10^6 |
| Viability at cell freezing (%) | 93.70 | Antibiotics Used | G418 |
| Passage Number | p7* | PDL | NT |
| Sterility: MYCOPLASMA | - | Sterility: BACTERIA | - |
| Sterility: FUNGI | - | Isozyme Analysis | NT |
| Chromosome Mode | NT | Chromosome Information | NT |
| Surface Antigen | NT | DNA Profile (STR) | D5S818:11,12 D13S317:8,12 D7S820:10,12 D16S539:10,11 VWA:14,16 TH01:9 AM:X TPOX:8,11 CSF1PO:11 |
| Adhesion | No | Exoteric Gene | NT |
| Medium for Freezing | BAMBANKER(LYMPHOTEC Inc.,CS-02-001,NIPPON Genetics Co., LTD) | CO2 Conc. | 5% |
| Viability immediately after thawing (%) | 73.9 | Additional information |
| Images |
|---|
|
|